FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
Read original at benzingaStocks · News reference
Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.074B Est
Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.074 billion estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 8:23 PM
- Checked
- Aug 6, 2026, 8:23 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating
William Blair analyst Steven Lichtman initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform rating.
Read original at benzingaInnovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth potential in the insulin pump market.
Read original at benzingaAirsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading include NAMI, BNED, YXT, TENX, MSC, B, VRSK, XFOR, HELP, and SLDB.
Read original at benzinga